What Happened?
Philadelphia, PA-based XyloCor Therapeutics Appointed Albert Gianchetti as President and Chief Executive Officer
About the Company
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. The Company`s lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing agreement with Weill Cornell Medicine for the worldwide rights to develop, manufacture and commercialize XC001.
About the Person
Albert Gianchetti is President and Chief Executive Officer at XyloCor Therapeutics. Previously, Albert held various senior HR leadership roles in the industry.
Info Source
News
Short Profile